Assay Detail
Binding
CHEMBL4266256
Review assay metadata, readout intent, target linkage, and publication context from the same page.
Inhibition of ALK (unknown origin)
3
Total Activities
3
Compounds Tested
1
Activity Types
0
Assay Parameters
Assay Information
| Assay Type | Binding |
| Organism | Homo sapiens |
| Confidence | 9 — Direct single protein target |
| Curated By | Autocuration |
Publication
First macrocyclic 3rd-generation ALK inhibitor for treatment of ALK/ROS1 cancer: Clinical and designing strategy update of lorlatinib.
Activity Statistics
| Type | Count | Avg pChEMBL | Best pChEMBL |
|---|---|---|---|
| Ki | 3 | 9.14 | 9.15 |
Compounds Tested
| Compound | Name | Phase | Activities | Best pChEMBL |
|---|---|---|---|---|
| CHEMBL3286830 | LORLATINIB | 4.0 | 1 | 9.15 |
| CHEMBL601719 | CRIZOTINIB | 4.0 | 1 | 9.13 |
| CHEMBL4286522 | — | — | 1 | - |
Activity Data
| Compound | Name | Type | Rel. | Value | Units | pChEMBL |
|---|---|---|---|---|---|---|
| CHEMBL3286830 | LORLATINIB | Ki | = | 0.7 | nM | 9.15 |
| CHEMBL601719 | CRIZOTINIB | Ki | = | 0.74 | nM | 9.13 |
| CHEMBL4286522 | — | Ki | < | 0.2 | nM | - |